Your browser doesn't support javascript.
loading
Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
Ghalandari, Nafise; Kemper, Erik; Crijns, Ineke Hubertina; Wolbink, Gertjan; Rispens, Theo; Smeele, Hieronymus Tw; Dolhain, Radboud Jem.
Afiliación
  • Ghalandari N; Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands n.ghalandari@erasmusmc.nl.
  • Kemper E; FT1/GMB, Medicines Evaluation Board, Utrecht, The Netherlands.
  • Crijns IH; Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Wolbink G; FT1/GMB, Medicines Evaluation Board, Utrecht, The Netherlands.
  • Rispens T; FT1/GMB, Medicines Evaluation Board, Utrecht, The Netherlands.
  • Smeele HT; Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
  • Dolhain RJ; Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands.
Ann Rheum Dis ; 81(3): 402-405, 2022 03.
Article en En | MEDLINE | ID: mdl-34493490
BACKGROUND: To minimise placental transfer of tumour necrosis factor inhibitors (TNFi), the European League Against Rheumatism (EULAR) created points to consider (PtC) for the use of TNFi during pregnancy. We are the first to validate the EULAR-PtC by analysing TNFi concentrations in cord blood. METHODS: Patients were derived from the Preconceptional Counselling in Active Rheumatoid Arthritis Study. TNFi was stopped at the time points recommended by the EULAR. Maternal blood and cord blood were collected and analysed for the concentration of TNFi. RESULTS: 111 patients were eligible for the analysis. Median stop time points were gestational age (GA) 37.0 weeks for certolizumab pegol, GA 25.0 weeks for etanercept, GA 19.0 weeks for adalimumab and GA 18.4 weeks for infliximab. Certolizumab pegol (n=68) was detectable in 5.9% of cord blood samples, with a median concentration of 0.3 µg/mL (IQR: 0.2-1.3) and a median cord/maternal concentration ratio of 0.010. Etanercept (n=30) was not detected in any cord blood samples. Adalimumab (n=25) was detectable in 48.0% of cord blood samples, with a median concentration of 0.5 µg/mL (IQR: 0.2-0.7) and a median concentration ratio of 0.062 (IQR: 0.018-0.15). Infliximab (n=14) was detectable in 57.1% of cord blood samples, with a median concentration of 0.4 µg/mL (IQR: 0.1-1.2) and a median concentration ratio of 0.012 (IQR: 0.006-0.081). CONCLUSION: Compliance with the EULAR-PtC results in absence or low levels of TNFi in cord blood.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complicaciones del Embarazo / Artritis Reumatoide / Reumatología / Sangre Fetal / Inhibidores del Factor de Necrosis Tumoral Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Ann Rheum Dis Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complicaciones del Embarazo / Artritis Reumatoide / Reumatología / Sangre Fetal / Inhibidores del Factor de Necrosis Tumoral Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Ann Rheum Dis Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido